Dihydrotanshinone I

Name: Dihydrotanshinone I
Brand: MedChemExpress
SKU: HY-N0360
Rating: 5.0 (5 reviews)

Cat. No.: HY-N0360 Purity: 99.57%: FAQs
Data Sheet SDS COA Handling Instructions

Molarity Calculator

Dihydrotanshinone I is a natural compound extracted from Salvia miltiorrhiza Bunge which has been widely used for treating cardiovascular diseases. Dihydrotanshinone I exhibits entry-blocking effect for MERS-CoV.

For research use only. We do not sell to patients.

Dihydrotanshinone I Chemical Structure

CAS No. : 87205-99-0

Size	Price	Stock	Quantity
Free Sample (0.1 - 0.5 mg)		Apply Now
5 mg	USD 77	In-stock	Estimated Time of Arrival: December 31
10 mg	USD 120	In-stock	Estimated Time of Arrival: December 31
25 mg	USD 252	In-stock	Estimated Time of Arrival: December 31
50 mg	USD 372	In-stock	Estimated Time of Arrival: December 31
100 mg		Get quote
200 mg		Get quote

or Bulk Inquiry

* Please select Quantity before adding items.

This product is a controlled substance and not for sale in your territory.

Customer Review

Based on 5 publication(s) in Google Scholar

Other Forms of Dihydrotanshinone I:

Dihydroisotanshinone I In-stock
Dihydrotanshinone I (Standard) Get quote

5 Publications Citing Use of MCE Dihydrotanshinone I

Featured Recommendations

•Related Screening Libraries:

•Related Small Molecules:

•Related Proteins:

Biological Activity
Protocol
Purity & Documentation
References
Customer Review

Description

Cellular Effect

Cell Line	Type	Value	Description	References
AGS	IC₅₀	> 50 μM Compound: 4, dihydrotanshinone i	Viability of human AGS cells under normoxic conditions after 24 hrs by MTT assay Viability of human AGS cells under normoxic conditions after 24 hrs by MTT assay	[PMID: 17583950]
AGS	IC₅₀	2.05 μM Compound: 4, dihydrotanshinone i	Inhibition of HIF1 activation in human AGS cells assessed as inhibition of hypoxia-induced luciferase expression after 16 hrs by reporter assay Inhibition of HIF1 activation in human AGS cells assessed as inhibition of hypoxia-induced luciferase expression after 16 hrs by reporter assay	[PMID: 17583950]
AGS	IC₅₀	47.7 μM Compound: 4, dihydrotanshinone i	Viability of human AGS cells under hypoxic conditions after 24 hrs by MTT assay Viability of human AGS cells under hypoxic conditions after 24 hrs by MTT assay	[PMID: 17583950]
Hep 3B2	IC₅₀	> 50 μM Compound: 4, dihydrotanshinone i	Viability of human Hep3B cells under normoxic conditions after 24 hrs by MTT assay Viability of human Hep3B cells under normoxic conditions after 24 hrs by MTT assay	[PMID: 17583950]
Hep 3B2	IC₅₀	> 50 μM Compound: 4, dihydrotanshinone i	Viability of human Hep3B cells under hypoxic conditions after 24 hrs by MTT assay Viability of human Hep3B cells under hypoxic conditions after 24 hrs by MTT assay	[PMID: 17583950]
Hep 3B2	IC₅₀	2.29 μM Compound: 4, dihydrotanshinone i	Inhibition of HIF1 activation in human Hep3B cells assessed as inhibition of hypoxia-induced luciferase expression after 16 hrs by reporter assay Inhibition of HIF1 activation in human Hep3B cells assessed as inhibition of hypoxia-induced luciferase expression after 16 hrs by reporter assay	[PMID: 17583950]
Hep 3B2	EC₅₀	5.5 μM Compound: 2	Cytotoxicity against human Hep3B cells deficient in p53 gene by MTT assay Cytotoxicity against human Hep3B cells deficient in p53 gene by MTT assay	[PMID: 20455578]
HepG2	EC₅₀	2.5 μM Compound: 2	Cytotoxicity against human HepG2 cells expressing wild type p53 gene by MTT assay Cytotoxicity against human HepG2 cells expressing wild type p53 gene by MTT assay	[PMID: 20455578]
HepG2	EC₅₀	4.7 μM Compound: 2	Cytotoxicity against doxorubicin resistant human HepG2 cells expressing wild type p53 gene by MTT assay Cytotoxicity against doxorubicin resistant human HepG2 cells expressing wild type p53 gene by MTT assay	[PMID: 20455578]
MCF7	IC₅₀	3.73 μM Compound: 1	Cytotoxicity against human MCF7 cells assessed as decrease in cell viability after 72 hrs by OZBlue assay Cytotoxicity against human MCF7 cells assessed as decrease in cell viability after 72 hrs by OZBlue assay	[PMID: 29313684]
MDA-MB-231	IC₅₀	8.99 μM Compound: 1	Cytotoxicity against human MDA-MB-231 cells assessed as decrease in cell viability after 72 hrs by OZBlue assay Cytotoxicity against human MDA-MB-231 cells assessed as decrease in cell viability after 72 hrs by OZBlue assay	[PMID: 29313684]
PANC-1	IC₅₀	2.91 μM Compound: 1	Cytotoxicity against human PANC1 cells assessed as decrease in cell viability after 72 hrs by OZBlue assay Cytotoxicity against human PANC1 cells assessed as decrease in cell viability after 72 hrs by OZBlue assay	[PMID: 29313684]
PLC-PRF-5	EC₅₀	> 10 μM Compound: 2	Cytotoxicity against human PLC/PRF/5 cells expressing mutant p53 gene (codon 249) by MTT assay Cytotoxicity against human PLC/PRF/5 cells expressing mutant p53 gene (codon 249) by MTT assay	[PMID: 20455578]

In Vitro

In lipopolysaccharide (LPS)-stimulated human umbilical vein endothelial cells (HUVECs), DHT (10 nM) decreases lectin-like ox-LDL receptor-1 (LOX-1) and NADPH oxidase 4 (NOX4) expression, reactive oxygen species (ROS) production, NF-κB nuclear translocation, ox-LDL endocytosis and monocytes adhesion^[1]. Dihydrotanshinone I induces caspase dependent apoptosis induced in HCT116 cells. Dihydrotanshinone I induces concentration and ROS dependent caspase activation. Apoptosis induced by Dihydrotanshinone I is completely prevented by Z-VAD-fmk. Apoptosis induced by Dihydrotanshinone I is significantly inhibited by pretreatment of Z-LEHD-fmk but only is partially inhibited by Z-IETD-fmk. Apoptosis induced by Dihydrotanshinone I is significantly increased by caspase-2 knockdown^[3].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

In Vivo

Dihydrotanshinone I (10 and 25 mg/kg) significantly attenuates atherosclerotic plaque formation, alteres serum lipid profile, decreases oxidative stress and shrinks necrotic core areas in ApoE^-/- mice. Dihydrotanshinone I dramatically inhibits the enhanced expression of LOX-1, NOX4, and NF-κB in aorta^[1].
Dihydrotanshinone I (1, 2, 4 mg/kg) treatment can improve cardiac function, reduce infarct size, ameliorate the variations in myocardial zymogram and histopathological disorders, decrease 20-HETE generation, and regulate apoptosis-related protein in myocardial ischemia-reperfusion rats^[2].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Molecular Weight

278.30

Formula

C₁₈H₁₄O₃

CAS No.

87205-99-0

Appearance

Solid

Color

Brown to red

SMILES

O=C(C1=C2C=CC3=C1C=CC=C3C)C(C4=C2OC[C@@H]4C)=O

Structure Classification

Initial Source

Shipping

Room temperature in continental US; may vary elsewhere.

Storage

Powder	-20°C	3 years
	4°C	2 years
In solvent	-80°C	1 year
	-20°C	6 months

Solvent & Solubility

In Vitro:

DMSO : 2 mg/mL (7.19 mM; Need ultrasonic; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)

Preparing
Stock Solutions

Concentration Solvent Mass	1 mg	5 mg	10 mg

1 mM	3.5932 mL	17.9662 mL	35.9324 mL
5 mM	0.7186 mL	3.5932 mL	7.1865 mL
10 mM	---	---	---

View the Complete Stock Solution Preparation Table

* Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 1 year; -20°C, 6 months. When stored at -80°C, please use it within 1 year. When stored at -20°C, please use it within 6 months.

Molarity Calculator
Dilution Calculator

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Concentration _(start) × Volume _(start) = Concentration _(final) × Volume _(final)

This equation is commonly abbreviated as: C₁V₁ = C₂V₂

Concentration _(start)

Volume _(start)

Concentration _(final)

Volume _(final)

In Vivo Dissolution Calculator

Please enter the basic information of animal experiments:

Dosage

mg/kg

Animal weight
(per animal)

Dosing volume
(per animal)

μL

Number of animals

Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.

Calculation results:

Working solution concentration: mg/mL

Purity & Documentation

Purity: 99.57%

Select Batch:

Data Sheet (285 KB) SDS (762 KB)

COA (257 KB) HNMR (191 KB) LCMS (104 KB)

Handling Instructions (2659 KB)

References

[1]. Zhao W, et al. Dihydrotanshinone I Attenuates Atherosclerosis in ApoE-Deficient Mice: Role of NOX4/NF-κB Mediated Lectin-Like Oxidized LDL Receptor-1 (LOX-1) of the Endothelium. Front Pharmacol. 2016 Nov 8;7:418. eCollection 2016. [Content Brief]

[2]. Wei Y, et al. The cardioprotection of dihydrotanshinone I against myocardial ischemia-reperfusion injury via inhibition of arachidonic acid ω-hydroxylase. Can J Physiol Pharmacol. 2016 Dec;94(12):1267-1275. Epub 2016 Jun 24. [Content Brief]

[3]. Wang L, et al. Dihydrotanshinone I induced apoptosis and autophagy through caspase dependent pathway in colon cancer. Phytomedicine. 2015 Nov 15;22(12):1079-87 [Content Brief]

[4]. Ji Yeun Kim, et al. Safe, High-Throughput Screening of Natural Compounds of MERS-CoV Entry Inhibitors Using a Pseudovirus Expressing MERS-CoV Spike Protein. Int J Antimicrob Agents. 2018 Nov;52(5):730-732. [Content Brief]

Kinase Assay ^[3]	Cells are treated with various concentrations of Dihydrotanshinone I (3.13-20 µM) for 48 h. For the activity assay, Ac-DEVD-AMC (1 µg/µL), Ac-IETD-AMC (1 µg/µL) or Ac-LEDH-AMC (1 µg/µL) and cell lysate are added into Protease Assay Buffer in 96-well plate. Reaction mixtures with lysis buffer are used as negative controls. Cells treated with DMSO (0.1%) are treated as vehicle control. The reaction mixtures are incubated for 1 h at 37°C. The AMC liberated from the substrates is measured using spectrofluorometer of Victor 2 plate reader with an excitation wavelength of 380 nm and an emission wavelength of 430 nm. MCE has not independently confirmed the accuracy of these methods. They are for reference only.
Animal Administration ^[1]	Male ApoE^-/- mice (6-8 weeks old) on C57BL/6J background and age-matched wild-type C57BL/6J controls housed in SPF-grade animal facilities with a 12 h light/dark cycle, at 23°C (±2°C). Starting from 6 weeks, the mice are fed with a HCD (54.35% raw grain, 20% lard, 0.15% cholesterol, 15% sucrose, 0.5% Sodium Cholate, 10% yolk powder) for 12 weeks. All ApoE^-/- mice are dosed daily via intragastric gavage with 10 and 25 mg/kg Dihydrotanshinone I dissolved in 0.5% CMC-Na or administered 0.5% CMC-Na alone (vehicle control) (n=8 per group). MCE has not independently confirmed the accuracy of these methods. They are for reference only.
References	[1]. Zhao W, et al. Dihydrotanshinone I Attenuates Atherosclerosis in ApoE-Deficient Mice: Role of NOX4/NF-κB Mediated Lectin-Like Oxidized LDL Receptor-1 (LOX-1) of the Endothelium. Front Pharmacol. 2016 Nov 8;7:418. eCollection 2016. [Content Brief] [2]. Wei Y, et al. The cardioprotection of dihydrotanshinone I against myocardial ischemia-reperfusion injury via inhibition of arachidonic acid ω-hydroxylase. Can J Physiol Pharmacol. 2016 Dec;94(12):1267-1275. Epub 2016 Jun 24. [Content Brief] [3]. Wang L, et al. Dihydrotanshinone I induced apoptosis and autophagy through caspase dependent pathway in colon cancer. Phytomedicine. 2015 Nov 15;22(12):1079-87 [Content Brief] [4]. Ji Yeun Kim, et al. Safe, High-Throughput Screening of Natural Compounds of MERS-CoV Entry Inhibitors Using a Pseudovirus Expressing MERS-CoV Spike Protein. Int J Antimicrob Agents. 2018 Nov;52(5):730-732. [Content Brief]

Complete Stock Solution Preparation Table

Optional Solvent	Concentration Solvent Mass	1 mg	5 mg	10 mg	25 mg

DMSO	1 mM	3.5932 mL	17.9662 mL	35.9324 mL	89.8311 mL
DMSO	5 mM	0.7186 mL	3.5932 mL	7.1865 mL	17.9662 mL